サンプル依頼リスト カート
  • English
  • Korean
表紙：頭頸部扁平上皮がんの世界市場-2023年～2030年
市場調査レポート
商品コード
1345392

頭頸部扁平上皮がんの世界市場-2023年～2030年

Global Head and Neck Squamous Cell Carcinoma Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
頭頸部扁平上皮がんの世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

頭頸部扁平上皮がんの世界市場は2022年に22億米ドルに達し、2023-2030年の予測期間中にCAGR 8.8％で成長し、2030年には43億米ドルに達すると予測されています。頭頸部扁平上皮がん市場は、罹患率と有病率の増加、研究の進展、研究開発活動の活発化、政府のイニシアティブなどの要因によって牽引されています。

口、喉、鼻腔を含む頭頸部領域の粘膜表面を覆う扁平上皮細胞は、頭頸部扁平上皮がんが発生する場所です。HNSCC市場は、支持療法、調査、治療など幅広いテーマをカバーしています。手術、放射線療法、化学療法、標的療法、免疫療法など、さまざまな治療法が含まれます。

市場力学

研究活動の活発化が世界の頭頸部扁平上皮がん市場の成長を牽引

例えば、2023年7月10日、米国頭頸部学会（AHNS）の第11回頭頸部がん国際会議（AHNS 2023）で、ASP-1929-181試験の新たなデータが発表されたと、独自のAlluminoxTMプラットフォームに基づく精密、細胞標的療法を開発・販売する世界のバイオテクノロジー企業であるRakuten Medical, Inc.が発表しました。

ASP-1929-181試験に登録された局所性および／または転移性の頭頸部扁平上皮がん（HNSCC）患者19名の予備的解析から、ASP-1929を用いたAlluminox治療と抗PD-1療法を併用する新規治療戦略が、患者において有望な初期結果を示したことが示唆されました。

頭頸部がんはPD-1治療が行われる腫瘍のひとつです。本試験の予備的知見から、再発頭頸部がんに対する新規の最先端治療としての可能性を評価するため、さらなる調査が必要です。抗腫瘍免疫応答は、EGFR＋腫瘍とPD-1遮断の両方を標的とする場合、どちらか一方の治療単独と比較して持続する腫瘍縮小の強化につながると予測されます。

世界の頭頸部扁平上皮がん市場の成長を牽引する積極的な主要企業

例えば、2023年6月、中国や他のアジア主要市場の患者にパラダイムシフトする医薬品を提供することにコミットしているバイオテクノロジー企業であるLianBio社と、がん患者の治療選択肢を拡大する物理学ベースのアプローチを開拓している後期臨床バイオテクノロジー企業であるNANOBIOTIX社は、最初の患者をランダム化することを発表した、NANORAY-312は、プラチナ製剤ベースの化学療法が不適格な高齢の局所進行がん・頸部扁平上皮がん（「LA-HNSCC」）患者を対象にNBTXR3を評価する国際共同第3相登録試験であり、アジアで最初の患者の無作為化を発表しました。

NANORAY-312は、高リスクで化学療法不適格の高齢のLA-HNSCC患者を対象に、セツキシマブ併用または非併用の放射線療法活性化NBTXR3の有効性と安全性を、セツキシマブ併用または非併用の放射線療法と比較することを目的とした、国際共同、2群間、無作為化、治験医師選択第Ⅲ相登録試験です。

頭頸部扁平上皮がん治療に伴う副作用が市場成長を妨げる

頭頸部扁平上皮がん薬物療法に伴う副作用が市場成長を抑制しています。化学療法の副作用には、嘔吐や吐き気、疲労、脱毛、出血、貧血、感染症、口内炎、食欲低下、便秘、下痢などのリスクを高める血球数の減少が含まれます。

標的治療の副作用には、発疹などの皮膚反応、下痢などの胃腸障害、疲労、血圧上昇、肝機能の変化、血液凝固や出血の可能性の増加、関節痛や筋肉痛などがあります。

また、免疫療法疲労、皮膚への反応（発疹、かゆみ）、インフルエンザの徴候（発熱、悪寒、体の痛みなど）、咳、息苦しさ、下痢または大腸炎内分泌系に関連する副作用（ホルモンバランスの乱れ、甲状腺機能不全）なども挙げられます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 研究活動の活発化
    • 抑制要因
      • 頭頸部扁平上皮がんに伴う副作用
    • 機会
      • 技術の進歩
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 タイプ別

  • 唾液腺
  • 口腔・口腔咽頭
  • 鼻腔・副鼻腔
  • 上咽頭
  • 喉頭
  • 低咽頭

第10章 薬剤クラス別

  • EGFR阻害剤
  • 免疫チェックポイント阻害薬
  • その他

第11章 投与経路別

  • 静脈内
  • 経口
  • その他

第12章 治療法別

  • 放射線療法
  • 化学療法
  • 免疫療法

第13章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター

第14章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第15章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第16章 企業プロファイル

  • Sanofi
    • 企業概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な動向
  • F. Hoffmann-La Roche Ltd.
  • Boehringer Ingelheim International GmbH.
  • GSK plc
  • Novartis AG
  • Bayer AG
  • Merck & Co., Inc.
  • AstraZeneca
  • Eli Lilly and Co
  • Cipla Inc.

第17章 付録

目次
Product Code: PH6758

Overview

Global Head and Neck Squamous Cell Carcinoma Market reached US$ 2.2 billion in 2022 and is expected to reach US$ 4.3 billion by 2030 growing with a CAGR of 8.8% during the forecast period 2023-2030. The head and neck squamous cell carcinoma market is driven by factors such as increasing incidence and prevalence, advancements in research, increased research and development activities, and government initiatives.

Squamous cells that line the mucosal surfaces of the head and neck region, including the mouth, throat, and nasal passages, are where head and neck squamous cell carcinoma develops. The HNSCC market covers a wide range of topics, including supportive care, research, and therapy. It includes a variety of therapeutic methods, including operations, radiation, chemotherapy, targeted therapy, and immunotherapy.

Market Dynamics

The Increasing Research Activities are Driving the Global Head and Neck Squamous Cell Carcinoma Market Growth

For instance, on July 10, 2023, new data from the ASP-1929-181 study was presented at the American Head and Neck Society's (AHNS) 11th International Conference on Head and Neck Cancer (AHNS 2023), according to Rakuten Medical, Inc., a global biotechnology company developing and marketing precision, cell targeting therapies based on its proprietary AlluminoxTM platform.

The preliminary analysis of 19 patients with locoregional and/or metastatic head and neck squamous cell carcinoma (HNSCC) who were enrolled in the ASP-1929-181 study suggested that the novel treatment strategy of Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy showed encouraging early results in patients.

Head and neck cancers are among the tumor types that are treated with PD-1 treatment. The preliminary findings of this study call for further investigation to assess its potential as a novel, cutting-edge therapy for recurrent head and neck cancer. The antitumor immune response is projected to lead to enhanced tumor-shrinking that is lasting compared to either treatment alone when targeting both EGFR + tumors and PD-1 blocking.

The Active Major Players are Driving the Global Head and Neck Squamous Cell Carcinoma Market Growth

For instance, in June 2023, LianBio, a biotechnology company committed to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment options for cancer patients, announced the randomization of the first patient in Asia in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced cancer and neck squamous cell carcinoma ("LA-HNSCC") who are ineligible for platinum-based chemotherapy.

In high-risk, chemotherapy-ineligible elderly patients with LA, NANORAY-312 is a global, two-arm, randomized, Investigator's Choice Phase 3 registrational study that aims to compare the effectiveness and safety of radiotherapy-activated NBTXR3 with or without cetuximab to radiotherapy with or without cetuximab.-HNSCC.

Side Effects Associated with Head and Neck Squamous Cell Carcinoma Therapy are Hampering the Market Growth

Side effects associated with head and neck squamous cell carcinoma medication therapy restraining the market growth. Chemotherapy's side effects include vomiting and nauseous, Fatigue, loss of hair lowered blood cell counts, which raises the risk of bleeding, anemia, infection mouth ulcers, and sores decrease in appetite, constipation, or diarrhea.

Targeted Treatment side effects include skin responses, such as rashes, gastrointestinal issues like diarrhea Fatigue, elevated blood pressure alterations in liver function, and increased chance of clotting or bleeding joint or muscle aches.

Immunotherapy Fatigue, responses on the skin (rash, itching), signs of the flu (such as fever, chills, and body aches), coughing, breathlessness, either diarrhea or colitis adverse effects relating to the endocrine system (hormone imbalances, thyroid malfunction).

Segment Analysis

The global head and neck squamous cell carcinoma market is segmented based on type, drug class, route of administration, treatment, end-user and region.

The Radiotherapy Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The radiotherapy segment accounted for the highest market stake accounting for approximately 45.4% of the head and neck squamous cell carcinoma market in 2022. The recommended course of treatment is high-dose cisplatin 100 mg/m2 administered concurrently with radiotherapy (RT) on days 1, 22, and 43. Alternative chemotherapy regimens with equivalent efficacy but less toxicity are preferred because this one has significant toxicity.

Recently, the prospective randomized phase II/III JCOG1008 research compared the effectiveness and safety of bolus cisplatin 100 mg/m2 administered every three weeks against weekly cisplatin 40 mg/m2 in 261 high-risk Asian LA-HNSCC patients planned for postoperative chemoradiation. Weekly cisplatin was found to be non-inferior with respect to the main endpoint OS at 3 years after a median follow-up of 2.2 years.

Geographical Penetration

North America Holds a Dominant Position in the Global Head and Neck Squamous Cell Carcinoma Market

North America is estimated to hold around 39.7% of the total market share in 2023. The active major players are driving the market in the North American region. For instance, in July 2022, Pliant stated that PLN-74809, an oral, dual-selective vB6/vB1 integrin inhibitor, has been given Fast Track designation by the U.S. Food and Drug Administration (FDA) for the possible treatment of Head and Neck squamous Cell Carcinoma (PSC).

The core treatment candidate of the Company, PLN-74809, is being evaluated in the INTEGRIS-PSC Phase 2a clinical trial (NCT04480840). In the first half of 2023, topline results from this randomized, double-blind, placebo-controlled trial in PSC patients are anticipated. As a result, the aforementioned elements support market expansion in the region.

Competitive Landscape

The major global players in the market include: Sanofi, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH., GSK plc, Novartis AG, Bayer AG, Merck & Co., Inc., AstraZeneca, Eli Lilly and Co, and Cipla Inc. among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the head and neck squamous cell carcinoma market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Access to medical knowledge and healthcare facilities may be hampered in areas that are directly affected by the conflict. This might affect our capacity to deliver efficient and timely HNSCC treatments.

If either Russia or Ukraine makes a substantial contribution to the study and development of HNSCC, the conflict may impede ongoing research and clinical trials, possibly delaying the release of novel and more effective therapies.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the head and neck squamous cell carcinoma market to improve various aspects of data analysis. To find new therapeutic molecules and forecast their effectiveness against HNSCC, AI is employed in the drug discovery process. It can mimic molecular interactions and forecast potential interactions between new medications and cancer cells.

Medical imaging data from CT scans, MRIs, and PET scans can be analyzed by AI algorithms to look for minute patterns and anomalies that can point to HNSCC. This can help with accurate diagnosis and early discovery, enabling prompt intervention.

By Type

  • Salivary Gland
  • Oral and Oropharyngeal
  • Nasal Cavity &Paranasal Sinuses
  • Nasopharyngeal
  • Laryngeal
  • Hypo Pharyngeal

By Drug Class

  • EGFR Inhibitors
  • Immune Checkpoint Inhibitors
  • Others

By Route of Administration

  • Intravenous
  • Oral
  • Others

By Treatment

  • Radiation
  • Chemotherapy
  • Immunotherapy

By End-user

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

By Region

  • North America

U.S.

Canada

Mexico

  • Europe

Germany

U.K.

France

Italy

Spain

Rest of Europe

  • South America

Brazil

Argentina

Rest of South America

  • Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

  • Middle East and Africa

Key Developments

  • In December 2022, NANOBIOTIX, a late-clinical-stage biotechnology company that has pioneered physics-based approaches to expand treatment options for cancer patients reported that the first patient in the United States has been randomized in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma ("LA-HNSCC") who are ineligible for platinum-based chemotherapy.

Why Purchase the Report?

  • To visualize the global head and neck squamous cell carcinoma market segmentation based on the type, drug class, route of administration, treatment, end-user and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of head and neck squamous cell carcinoma market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global head and neck squamous cell carcinoma market report would provide approximately 69 tables, 72 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Drug Class
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Treatment
  • 3.5. Snippet by End-user
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising research activities
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with head and neck squamous cell carcinoma
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.1.2. Market Attractiveness Index, By Type
  • 9.2. Salivary Gland *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Oral and Oropharyngeal
  • 9.4. Nasal Cavity &Paranasal Sinuses
  • 9.5. Nasopharyngeal
  • 9.6. Laryngeal
  • 9.7. Hypo Pharyngeal

10. By Drug Class

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.1.2. Market Attractiveness Index, By Drug Class
  • 10.2. EGFR Inhibitors*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Immune Checkpoint Inhibitors
  • 10.4. Others

11. By Route of Administration

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.1.2. Market Attractiveness Index, By Route of Administration
  • 11.2. Intravenous*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Oral
  • 11.4. Others

12. By Treatment

    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.1.2. Market Attractiveness Index, By Treatment
  • 12.2. Radiation*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Chemotherapy
  • 12.4. Immunotherapy

13. By End-user

    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.1.2. Market Attractiveness Index, By End-user
  • 13.2. Hospitals*
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Specialty Clinics
  • 13.4. Ambulatory Surgical Centers

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key Region-Specific Dynamics
    • 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 14.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.2.8.1. U.S.
      • 14.2.8.2. Canada
      • 14.2.8.3. Mexico
  • 14.3. Europe
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 14.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.3.8.1. Germany
      • 14.3.8.2. U.K.
      • 14.3.8.3. France
      • 14.3.8.4. Italy
      • 14.3.8.5. Spain
      • 14.3.8.6. Rest of Europe
  • 14.4. South America
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 14.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.4.8.1. Brazil
      • 14.4.8.2. Argentina
      • 14.4.8.3. Rest of South America
  • 14.5. Asia-Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 14.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.5.8.1. China
      • 14.5.8.2. India
      • 14.5.8.3. Japan
      • 14.5.8.4. Australia
      • 14.5.8.5. Rest of Asia-Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 14.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

15. Competitive Landscape

  • 15.1. Competitive Scenario
  • 15.2. Product Benchmarking
  • 15.3. Company Share Analysis
  • 15.4. Key Developments and Strategies

16. Company Profiles

    • 16.1.1. Sanofi*
      • 16.1.1.1. Company Overview
      • 16.1.1.2. Product Portfolio and Description
      • 16.1.1.3. Financial Overview
      • 16.1.1.4. Key Developments
    • 16.1.2. F. Hoffmann-La Roche Ltd.
    • 16.1.3. Boehringer Ingelheim International GmbH.
    • 16.1.4. GSK plc
    • 16.1.5. Novartis AG
    • 16.1.6. Bayer AG
    • 16.1.7. Merck & Co., Inc.
    • 16.1.8. AstraZeneca
    • 16.1.9. Eli Lilly and Co
    • 16.1.10. Cipla Inc.

LIST NOT EXHAUSTIVE

17. Appendix

  • 17.1. About Us and Services
  • 17.2. Contact Us